Global Allogeneic Cell Therapy Market Size study & Forecast, by Therapy Type (Stem Cell Therapies, Non-stem Cell Therapies), by Therapeutic Area (Hematological Disorders, Dermatological Disorders and Others), and Regional Analysis, 2023-2030
Global Allogeneic Cell Therapy Market is valued at approximately USD 255.6 million in 2022 and is anticipated to grow with a healthy growth rate of more than 27.40% over the forecast period 2023-2030. Allogeneic cell therapy is a type of cellular therapy that involves the use of cells from a donor to treat a patient. In this type of therapy, cells are collected from a healthy donor and are then processed and expanded in a laboratory setting before being infused into the patient. The cells used in allogeneic cell therapy can be various types of cells, including stem cells, immune cells, or other specialized cells that have therapeutic potential. The cells are typically selected based on their ability to replace damaged or dysfunctional cells in the patient's body or to modulate the immune system to fight a particular disease. The Allogeneic Cell Therapy Market is being driven by factors such as the rising prevalence of cancer and increasing FDA approvals of allogeneic cell therapies.
Allogeneic cell therapy has been used to treat a range of diseases, including cancer, genetic disorders, and autoimmune diseases. The therapy has shown promising results in clinical trials, and researchers are continuing to investigate its potential for treating a variety of conditions. The rising prevalence of cancer globally is fostering market growth, according to estimates from the International Agency for Research on Cancer (IARC), it is estimated that worldwide burden of cancer is projected to reach 27.5 million new cases by 2040 from 1.9 million new cases in the year 2021. Clinical trials for cell therapies have increased as a result of the growing demand for cutting-edge medical treatments for chronic disorders. According to information provided by, there were 1,358 active cell therapy trials as of April 2021, up from 24% from 2019 to 2020 and a 43% rise from 2020 to 2021. Clinical studies for CAR-T cells, which have expanded by 83%, account for most of this expansion. Thus, the rising number of clinical trials across the world is catering the market growth. In addition, increasing government funding for stem cell therapies and rising cell-based clinical trial activities are creating lucrative growth in the market. The BLA is planned to be submitted by the end of Q4 2023. The successful launch of this Therapy Typemay provides patients with an alternative option. However, the high cost of Allogeneic Cell Therapy stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Allogeneic Cell Therapy Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in 2022 as a result of the popularity of branded goods and the region's rising disease rates. Approximately 37.3 million Americans will have diabetes in 2020, including 28.7 million cases that have already received a diagnosis and 8.5 million cases that haven't. Asia Pacific is anticipated to grow at the highest CAGR during the forecast period due to factors like expanding geriatric and target populations, an increase in the number of collaborations for biosimilar development, geographic expansion of key players, and active participation of governmental and nonprofit organizations in the market space.
Major market player included in this report are:JCR Pharmaceuticals Co., Ltd.
Sumitomo Pharma Co., Ltd.
Atara Biotherapeutics Inc.
Mallinckrodt Pharmaceuticals
Tego Science Inc.
Takeda Pharmaceutical Company Limited.
STEMPEUTICS RESEARCH PVT LTD.
Biosolution Co., Ltd.
MEDIPOST Co., Ltd.
LifeSouth Community Blood Centers, Inc.
Recent Developments in the Market: In January 2022, Bristol Myers Squibb, and Century Therapeutics collaborated to create allogeneic therapies for solid tumours and hematologic malignancies using iPSC-derived stem cells.
In October 2022, Allogene Therapeutics introduces CAR T TogetherTM, a groundbreaking collaboration with leading oncologists across the nation, with the aim of speeding the development and enrollment in clinical trials for investigational ""off-the-shelf"" allogeneic , chimeric antigen receptor (CAR) T products to make CAR T therapy scalable and more accessible to patients with certain cancers.
Global Allogeneic Cell Therapy Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Therapy Type, Therapeutic Area, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Therapy Typeofferings of key players.
The detailed segments and sub-segment of the market are explained below:By Therapy Type:
Stem Cell Therapies
Non-stem Cell Therapies
By Therapeutic Area:
Hematological Disorders
Dermatological Disorders
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa
Companies MentionedJCR Pharmaceuticals Co., Ltd.
Sumitomo Pharma Co., Ltd.
Atara Biotherapeutics Inc.
Mallinckrodt Pharmaceuticals
Tego Science Inc.
Takeda Pharmaceutical Company Limited.
STEMPEUTICS RESEARCH PVT LTD.
Biosolution Co., Ltd.
MEDIPOST Co., Ltd.
LifeSouth Community Blood Centers, Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.